GET3

Summary

GET3 (guided entry of tail-anchored proteins factor 3, ATPase, HGNC:752) is a protein-coding gene on chromosome 19p13.13, encoding ATPase GET3 (O43681). ATPase required for the post-translational delivery of tail-anchored (TA) proteins to the endoplasmic reticulum. It is a selective cancer dependency (DepMap: 71.6% of cell lines).

This gene represents the human homolog of the bacterial arsA gene, encoding the arsenite-stimulated ATPase component of the arsenite transporter responsible for resistance to arsenicals. This protein is also a central component of a transmembrane domain (TMD) recognition complex (TRC) that is involved in the post-translational delivery of tail-anchored (TA) proteins from the cytosol to the endoplasmic reticulum (ER). It recognizes and selectively binds the TMD of TA proteins in the cytosol, and delivers them to the ER for insertion.

Source: NCBI Gene 439 — RefSeq curated summary.

At a glance

• Gene–disease (curated): cardiomyopathy, dilated, 2H (Limited, ClinGen) — +1 more curated relationship
• Clinical variants (ClinVar): 42 total — 1 pathogenic
• GTEx eGene: eQTL in 6 tissues, sQTL in 1 (q < 0.05)
• Phenotypes (HPO): 22
• Cancer dependency (DepMap): dependent in 71.6% of screened cell lines
• Constraint (gnomAD): pLI 0.03 (LoF-tolerant), LOEUF 0.73 (unconstrained)
• MANE Select transcript: NM_004317
• Interaction hub: 1,738 STRING partners (top 10% of genes corpus-wide)

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:752
Approved symbol	GET3
Name	guided entry of tail-anchored proteins factor 3, ATPase
Location	19p13.13
Locus type	gene with protein product
Status	Approved
Aliases	ARSA-I, TRC40
Ensembl gene	ENSG00000198356
Ensembl biotype	protein_coding
OMIM	601913
Entrez	439

Gene structure

Transcript identifiers

Ensembl transcripts: 23 — 17 protein_coding, 5 nonsense_mediated_decay, 1 retained_intron

MANE Select: ENST00000357332

Transcript support level (Ensembl TSL; 1 = fully mRNA-supported): TSL 1: 1, TSL 2: 1, TSL 5: 1

ENST00000357332, ENST00000590633, ENST00000591090, ENST00000904140, ENST00000904141, ENST00000904142, ENST00000935714, ENST00000935715, ENST00000935716, ENST00000935717, ENST00000935718, ENST00000935719, ENST00000935720, ENST00000935721, ENST00000935722, ENST00000973363, ENST00001066119, ENST00001066120, ENST00001066121, ENST00001066125, ENST00001094027, ENST00001094028, ENST00001120267

RefSeq mRNA: 3 — MANE Select: NM_004317 NM_001371488, NM_001371489, NM_004317

CCDS: CCDS32920

Canonical transcript exons

ENST00000357332 — 7 exons

Exon	Start	End
ENSE00000681706	12747395	12747592
ENSE00000681709	12747197	12747304
ENSE00000681719	12745377	12745525
ENSE00000836333	12747973	12748323
ENSE00001425509	12737497	12737666
ENSE00001505519	12745609	12745759
ENSE00003684440	12738511	12738658

Expression profiles

Bgee: expression breadth ubiquitous, 283 present calls, max score 96.23.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 34.4239 / max 172.4390, expressed in 1820 samples.

Highest expression (Bgee): monocyte, stromal cell of endometrium, prefrontal cortex, adrenal gland, apex of heart.

Genetic regulation across tissues (GTEx eQTL / sQTL)

GET3 is an eGene in GTEx v10 — its expression is genetically regulated (eQTL) in 6 tissues and its splicing (sQTL) in 1 (q < 0.05). Strongest associations first; slope = normalized effect of the lead variant’s alternative allele.

7 significant tissue × QTL associations:

Tissue	QTL	q-value	Slope	Lead variant
Ovary	eqtl	7.5e-04	-0.68	19:12831272:G:T
Brain Cerebellar Hemisphere	eqtl	4.0e-03	-0.36	19:12998987:C:T
Skin Sun Exposed Lower leg	eqtl	7.4e-03	-0.29	19:13206785:CTGG:C
Heart Atrial Appendage	eqtl	2.3e-02	+0.09	19:11771792:A:G
Artery Tibial	eqtl	3.0e-02	-0.17	19:11882535:A:G
Cells Cultured fibroblasts	eqtl	4.5e-02	+0.22	19:13736861:G:A
Artery Coronary	sqtl	4.9e-02	-0.58	19:13432241:C:A

FANTOM5 promoters

2 alternative TSS:

Promoter ID	TPM avg	Samples expressed
174009	32.6554	1817
174008	1.7685	1303

Top tissues by expression

showing 100 of 294 tissues by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
monocyte	CL:0000576	96.23	gold quality
stromal cell of endometrium	CL:0002255	96.15	gold quality
prefrontal cortex	UBERON:0000451	96.11	gold quality
right adrenal gland	UBERON:0001233	96.07	gold quality
apex of heart	UBERON:0002098	96.04	gold quality
right adrenal gland cortex	UBERON:0035827	95.92	gold quality
mononuclear cell	CL:0000842	95.89	gold quality
leukocyte	CL:0000738	95.84	gold quality
right frontal lobe	UBERON:0002810	95.84	gold quality
left adrenal gland	UBERON:0001234	95.69	gold quality
right testis	UBERON:0004534	95.65	gold quality
islet of Langerhans	UBERON:0000006	95.60	gold quality
granulocyte	CL:0000094	95.56	gold quality
left adrenal gland cortex	UBERON:0035825	95.49	gold quality
left testis	UBERON:0004533	95.46	gold quality
endometrium epithelium	UBERON:0004811	95.22	gold quality
cingulate cortex	UBERON:0003027	95.08	gold quality
heart left ventricle	UBERON:0002084	95.05	gold quality
anterior cingulate cortex	UBERON:0009835	95.01	gold quality
metanephros cortex	UBERON:0010533	94.92	gold quality
skin of leg	UBERON:0001511	94.77	gold quality
cardiac ventricle	UBERON:0002082	94.76	gold quality
mucosa of transverse colon	UBERON:0004991	94.76	gold quality
body of stomach	UBERON:0001161	94.72	gold quality
cortical plate	UBERON:0005343	94.71	gold quality
nucleus accumbens	UBERON:0001882	94.67	gold quality
amygdala	UBERON:0001876	94.63	gold quality
adrenal cortex	UBERON:0001235	94.59	gold quality
caudate nucleus	UBERON:0001873	94.55	gold quality
skin of abdomen	UBERON:0001416	94.46	gold quality
right lobe of thyroid gland	UBERON:0001119	94.31	gold quality
ganglionic eminence	UBERON:0004023	94.30	gold quality
ectocervix	UBERON:0012249	94.30	gold quality
adenohypophysis	UBERON:0002196	94.27	gold quality
right atrium auricular region	UBERON:0006631	94.23	gold quality
hindlimb stylopod muscle	UBERON:0004252	94.22	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	94.22	gold quality
esophagogastric junction muscularis propria	UBERON:0035841	94.20	gold quality
left lobe of thyroid gland	UBERON:0001120	94.18	gold quality
left coronary artery	UBERON:0001626	94.14	gold quality
gall bladder	UBERON:0002110	94.13	gold quality
gastrocnemius	UBERON:0001388	94.07	gold quality
right hemisphere of cerebellum	UBERON:0014890	94.02	gold quality
endocervix	UBERON:0000458	93.96	gold quality
lower esophagus	UBERON:0013473	93.89	gold quality
lower esophagus muscularis layer	UBERON:0035833	93.89	gold quality
cerebellar hemisphere	UBERON:0002245	93.83	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	93.83	gold quality
adrenal gland	UBERON:0002369	93.82	gold quality
thoracic aorta	UBERON:0001515	93.79	gold quality
cerebellar cortex	UBERON:0002129	93.79	gold quality
adult mammalian kidney	UBERON:0000082	93.77	gold quality
esophagus mucosa	UBERON:0002469	93.77	gold quality
mucosa of stomach	UBERON:0001199	93.75	gold quality
right coronary artery	UBERON:0001625	93.75	gold quality
putamen	UBERON:0001874	93.74	gold quality
minor salivary gland	UBERON:0001830	93.73	gold quality
muscle of leg	UBERON:0001383	93.72	gold quality
ascending aorta	UBERON:0001496	93.72	gold quality
ventricular zone	UBERON:0003053	93.71	gold quality
esophagus	UBERON:0001043	93.70	gold quality
heart	UBERON:0000948	93.67	gold quality
Brodmann (1909) area 9	UBERON:0013540	93.67	gold quality
popliteal artery	UBERON:0002250	93.64	gold quality
tibial artery	UBERON:0007610	93.64	gold quality
aorta	UBERON:0000947	93.63	gold quality
testis	UBERON:0000473	93.60	gold quality
pituitary gland	UBERON:0000007	93.59	gold quality
transverse colon	UBERON:0001157	93.59	gold quality
left uterine tube	UBERON:0001303	93.56	gold quality
descending thoracic aorta	UBERON:0002345	93.53	gold quality
omental fat pad	UBERON:0010414	93.48	gold quality
peritoneum	UBERON:0002358	93.46	gold quality
coronary artery	UBERON:0001621	93.44	gold quality
right ovary	UBERON:0002118	93.41	gold quality
right uterine tube	UBERON:0001302	93.34	gold quality
cardiac atrium	UBERON:0002081	93.32	gold quality
body of pancreas	UBERON:0001150	93.27	gold quality
upper lobe of left lung	UBERON:0008952	93.25	gold quality
hypothalamus	UBERON:0001898	93.21	gold quality
body of uterus	UBERON:0009853	93.15	gold quality
spinal cord	UBERON:0002240	93.03	gold quality
frontal cortex	UBERON:0001870	93.02	gold quality
thyroid gland	UBERON:0002046	92.96	gold quality
neocortex	UBERON:0001950	92.95	gold quality
muscle layer of sigmoid colon	UBERON:0035805	92.89	gold quality
cerebellum	UBERON:0002037	92.78	gold quality
adipose tissue of abdominal region	UBERON:0007808	92.76	gold quality
left ovary	UBERON:0002119	92.59	gold quality
pancreas	UBERON:0001264	92.51	gold quality
mouth mucosa	UBERON:0003729	92.44	gold quality
zone of skin	UBERON:0000014	92.41	gold quality
stomach	UBERON:0000945	92.33	gold quality
small intestine Peyer’s patch	UBERON:0003454	92.30	gold quality
forebrain	UBERON:0001890	92.27	gold quality
upper lobe of lung	UBERON:0008948	92.26	gold quality
smooth muscle tissue	UBERON:0001135	92.24	gold quality
telencephalon	UBERON:0001893	92.17	gold quality
lower esophagus mucosa	UBERON:0035834	92.15	gold quality
olfactory segment of nasal mucosa	UBERON:0005386	92.08	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	11.10

HPA expression

RNA tissue specificity: Low tissue specificity

showing 60 of 80 HPA tissues / cells by nTPM:

Tissue / cell	Axis	nTPM	Protein (IHC)
Frontal cortex	tissue	155.7
Caudate putamen	tissue	134.2
Thalamus	tissue	128.1
Superior colliculi	tissue	124.6
Pons	tissue	121.1
Midbrain	tissue	115.2
Cerebral cortex	tissue	103.7	medium
Somatosensory cortex	tissue	103.7
Medulla oblongata	tissue	103.6
Putamen	tissue	103.0
Hippocampal formation	tissue	102.8
Occipital cortex	tissue	99.5
Substantia nigra	tissue	98.7
Spinal cord	tissue	94.3
Prefrontal cortex	tissue	93.6
Motor cortex	tissue	93.2
Basal ganglia	tissue	92.9	medium
Temporal cortex	tissue	89.7
Entorhinal cortex	tissue	89.0
Septum	tissue	88.5
Hypothalamus	tissue	88.1
Periaqueductal gray	tissue	87.6
Ventral forebrain	tissue	86.8
Retrosplenial and cingulate cortex	tissue	84.0
Retrosplenial cortex	tissue	78.6
Cerebellum	tissue	78.2	high
Corpus callosum	tissue	77.5
Insular cortex	tissue	71.8
Olfactory bulb	tissue	69.5
Parathyroid gland	tissue	68.9	low
Amygdala	tissue	67.9
Choroid plexus	tissue	64.2
Bone marrow	tissue	62.5	low
Skeletal muscle	tissue	61.0	not detected
Heart muscle	tissue	58.1	low
Tongue	tissue	54.8
Thyroid gland	tissue	52.7	high
Ovary	tissue	52.6	high
Kidney	tissue	51.6	high
Postcentral gyrus	tissue	51.6
Esophagus	tissue	49.3	medium
Hippocampus	tissue	48.8	medium
Pituitary gland	tissue	48.2
Nucleus accumbens	tissue	47.6
Locus coeruleus	tissue	47.0
Pancreas	tissue	45.4	medium
Lymph node	tissue	45.2	medium
Adrenal gland	tissue	44.7	medium
Fallopian tube	tissue	44.2	high
Skin 1	tissue	44.1	medium
Thymus	tissue	43.7
Urinary bladder	tissue	43.3	high
Vagina	tissue	42.8	medium
Salivary gland	tissue	41.5	medium
Epididymis	tissue	38.7	high
Testis	tissue	37.8	high
Duodenum	tissue	37.6	high
Appendix	tissue	37.1	medium
Gallbladder	tissue	36.8	medium
Tonsil	tissue	35.7	high

Brain sub-regions (HPA Brain Atlas): detected in 192; highest nTPM — Dorsal hippocampus (102.8), Ventral spinal cord (94.3), Ventral hippocampus (91.9), Dorsal spinal cord (88.4), Subiculum (81.5).

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

Targeting GET3 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific).

29 miRNAs:

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-574-5P	100.00	66.01	989
HSA-MIR-6798-5P	100.00	65.77	699
HSA-MIR-19A-3P	99.98	75.33	2762
HSA-MIR-19B-3P	99.98	75.44	2754
HSA-MIR-6825-5P	99.96	69.81	3431
HSA-MIR-1250-3P	99.96	70.04	4038
HSA-MIR-153-5P	99.89	73.86	6317
HSA-MIR-6756-5P	99.82	67.97	2466
HSA-MIR-6794-5P	99.76	66.38	1048
HSA-MIR-4716-3P	99.69	66.73	1022
HSA-MIR-6134	99.63	65.68	1537
HSA-MIR-2113	99.58	71.22	1521
HSA-MIR-6731-5P	99.28	67.42	2375
HSA-MIR-8085	99.28	67.56	2362
HSA-MIR-7109-5P	99.18	66.13	1057
HSA-MIR-4758-3P	99.12	63.96	869
HSA-MIR-328-5P	99.08	64.65	1000
HSA-MIR-4709-3P	98.88	68.04	1594
HSA-MIR-6885-5P	98.71	64.33	902
HSA-MIR-6887-5P	98.56	68.49	1295
HSA-MIR-6795-5P	98.52	68.51	1277
HSA-MIR-6804-5P	98.39	65.77	1084
HSA-MIR-1233-5P	98.19	66.71	1201
HSA-MIR-6778-5P	98.19	66.59	1239
HSA-MIR-10398-5P	97.12	64.94	1051
HSA-MIR-1913	97.07	66.20	1417
HSA-MIR-5694	97.06	67.70	682
HSA-MIR-4652-5P	96.46	64.22	553
HSA-MIR-885-3P	95.14	63.08	448

Functional genomics

gnomAD constraint: pLI 0.0327, LOEUF 0.734, missense Z 2.19 — population loss-of-function intolerance (pLI ≥ 0.9 = LoF-intolerant; lower LOEUF = more constrained). gnomAD

Regional missense constraint (gnomAD)

ENST00000357332 splits into 3 regions with different missense tolerance; 0 are missense-constrained. Missense variants in a constrained region (low observed/expected) are more likely to be pathogenic. gnomAD

Region (GRCh38)	Missense obs / exp	o/e	Constrained
19:12,737,506–12,737,591	64 / 36.7	1.74	no
19:12,737,592–12,748,024	230 / 389.2	0.59	no
19:12,748,025–12,748,101	39 / 33.0	1.18	no
DepMap (CRISPR cell-line fitness): dependent in 71.6% of screened cell lines.

Most-dependent cell lines (DepMap gene-effect, lower = stronger; ≤ −0.5 shown): OCI-AML2 (-2.238), HT-29 (-2.061), 769-P (-1.98), TC-71 (-1.977), PC-14 (-1.96), OE21 (-1.939), KMRC-3 (-1.926), LP-1 (-1.916), DK-MG (-1.897), C2BBe1 (-1.885), SK-BR-3 (-1.805), SU-DHL-5 (-1.793), HCC1806 (-1.766), Caov-4 (-1.738), SNU-16 (-1.699).

Literature-anchored findings (GeneRIF, showing 18)

• Human ASNA1 is highly expressed in pancreatic beta cells, but not in other pancreatic endocrine cell types, and regulates insulin secretion in cultured cells. (PMID:17289575)
• TRC40/Asna-1 interacts posttranslationally with tail-anchored proteins in a transmembrane domain-dependent manner for delivery to a proteinaceous receptor at the endoplasmic reticulum membrane. (PMID:17382883)
• the hydrophobicity of the TA region dictates whether a precursor is delivered to the ER via the Hsp40/Hsc70 or Asna-1/TRC40-dependent route. (PMID:18667436)
• ASNA1 is a target to overcome platinum resistance in ovarian cancer (PMID:19724867)
• Asna1 can mediate membrane insertion of RAMP4 and Sec61beta without the participation of other cytosolic proteins by a mechanism that depends on the presence of ATP or ADP and a protease-sensitive receptor in the endoplasmic reticulum membrane. (PMID:20375064)
• Asna1 is required for efficient histocompatibility (HLA) class I downregulation mediated by viral protein BNLF2a. (PMID:21296983)
• The coiled-coil domain of WRB is the binding site for TRC40/Asna1. (PMID:21444755)
• Post-translational membrane insertion of tail-anchored transmembrane EF-hand Ca2+ sensor calneurons requires the TRC40/Asna1 protein chaperone. (PMID:21878631)
• Proteins bind to TRC40 and can utilise this component for their delivery to the ER membrane. (PMID:22505607)
• Results indicate calcium-modulating cyclophilin ligand (CAML) and WRB as components of the TRC40 receptor complex and a crucial mechanism for driving ER membrane insertion of TA proteins in mammalian cells. (PMID:23041287)
• PEX19 formed a complex with the peroxisomal tail anchored protein PEX26 in the cytosol and translocated it directly to peroxisomes by a TRC40-independent class I pathway. (PMID:23460677)
• The repertoire of VAPB interactors is more diverse than previously anticipated and link VAPB to the function of ATPase complexes such as p97/FAF1 and ASNA1/transmembrane-domain recognition complex. (PMID:24885147)
• Emerin interacts with TRC40 in situ. (PMID:26675233)
• reveal unanticipated complexity in the mutual regulation of the TRC40 receptor subunits and raise the question as to the role of the excess CAML in the endoplasmic reticulum (PMID:27226539)
• The authors conclude that the TRC40 pathway is critical for hearing and propose that otoferlin is an essential substrate of this pathway in hair cells. (PMID:27458190)
• Asna1/TRC40 is required at a late step of herpes simplex virus type 1 infection for efficient release of mature virions to the extracellular milieu. (PMID:27765046)
• Golgi-resident tail-anchored proteins such as the golgins golgin-84, CASP and giantin as well as the vesicle-associated membrane-protein-associated proteins VAPA and VAPB interact with TRC40. (PMID:31182645)
• Mutation in ASNA1 cause severe pediatric cardiomyopathy and early death. (PMID:31461301)

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	get3	ENSDARG00000018190
mus_musculus	Get3	ENSMUSG00000052456
rattus_norvegicus	Get3	ENSRNOG00000003747
drosophila_melanogaster	CG1598	FBGN0033191
caenorhabditis_elegans		WBGENE00014025

Mouse-model phenotypes

Observed phenotypes of the mouse ortholog (MGI:1928379) from MGI (Alliance of Genome Resources) — knockout/mutant phenotypes, ranked by annotation count. 1 distinct phenotype terms.

Mouse phenotype (MP)	Records
embryonic lethality, complete penetrance	1

Additional cross-species homologs

Sequence homologs in species beyond Ensembl Compara’s model organisms, by Diamond local protein alignment (% sequence identity; best hit per species). Lower-identity rows are more distant homologs. The matched accessions’ gene symbols aren’t in biobtree yet, so each row shows the UniProt accession.

Organism	UniProt	Identity	Method
Bos taurus	A5PJI5	100.0%	Diamond
Histoplasma mississippiense	A6QRP2	100.0%	Diamond
Saccharomyces cerevisiae YJM789	A6ZXM9	100.0%	Diamond
Aspergillus fumigatus A1163	B0XXL5	100.0%	Diamond
Saccharomyces cerevisiae RM11-1a	B3LGZ3	100.0%	Diamond
Aspergillus flavus NRRL3357	B8N3P7	100.0%	Diamond
Paracoccidioides brasiliensis Pb03	C0S3F7	100.0%	Diamond
Paracoccidioides brasiliensis Pb18	C1G182	100.0%	Diamond
Blastomyces dermatitidis ER-3	C5G9V3	100.0%	Diamond
Blastomyces gilchristii SLH14081	C5JUG0	100.0%	Diamond
Coccidioides posadasii C735 delta SOWgp	C5P9K5	100.0%	Diamond
Histoplasma capsulatum H143	C6HRP6	100.0%	Diamond
Candida albicans SC5314	P0CB54	100.0%	Diamond
Candida albicans WO-1	P0CB55	100.0%	Diamond
Cryptococcus deneoformans JEC21	P0CM24	100.0%	Diamond
Cryptococcus deneoformans B-3501A	P0CM25	100.0%	Diamond
Saccharomyces cerevisiae S288C	Q12154	100.0%	Diamond
Coccidioides immitis RS	Q1E167	100.0%	Diamond
Aspergillus oryzae RIB40	Q2UKT0	100.0%	Diamond
Aspergillus fumigatus Af293	Q4WY07	100.0%	Diamond
Aspergillus fischeri NRRL 181	A1D6T7	99.4%	Diamond
Botrytis cinerea B05.10	A6S7T2	99.4%	Diamond
Sclerotinia sclerotiorum 1980 UF-70	A7EHP6	99.4%	Diamond
Histoplasma capsulatum G186AR	C0NV23	99.4%	Diamond
Drosophila persimilis	B4H8J5	99.1%	Diamond
Drosophila simulans	B4QEC4	99.1%	Diamond
Drosophila pseudoobscura pseudoobscura	Q28YJ2	99.1%	Diamond
Drosophila erecta	B3N9X2	98.8%	Diamond
Drosophila yakuba	B4P1R6	98.8%	Diamond
Paracoccidioides lutzii Pb01	C1GTV2	98.8%	Diamond
Talaromyces marneffei ATCC 18224	B6Q334	98.5%	Diamond
Talaromyces stipitatus ATCC 10500	B8M4Y9	98.5%	Diamond
Xenopus tropicalis	Q0IIZ2	98.5%	Diamond
Xenopus laevis	Q6GNQ1	98.5%	Diamond
Candida dubliniensis CD36	B9W757	98.3%	Diamond
Drosophila mojavensis	B4KTG7	97.9%	Diamond
Drosophila virilis	B4LN33	97.9%	Diamond
Drosophila ananassae	B3MHB7	97.6%	Diamond
Plasmodium vivax Sal-1	A5K5W9	97.1%	Diamond
Plasmodium knowlesi strain H	B3L1G8	97.1%	Diamond

Genomic neighbors (locus context)

Genes flanking this one on the chromosome (NCBI/Entrez gene neighborhood). Positional context only — some neighbors share regulatory elements (bidirectional promoters, antisense/overlapping transcripts), but chromosomal adjacency is not itself a functional relationship (see Interactions for that).

Symbol	Type	Entrez
HOOK2	protein-coding	29911
JUNB	protein-coding	3726
BEST2	protein-coding	54831
PRDX2	protein-coding	7001
SNORD135	snoRNA	106633804
SNORD41	snoRNA	26810
TNPO2	protein-coding	30000
TRIR	protein-coding	79002
MIR5684	ncRNA	100847071
FBXW9	protein-coding	84261
THSD8	protein-coding	111644133
GNG14	protein-coding	105372280

Protein

Protein identifiers

ATPase GET3 — O43681 (reviewed: O43681)

Alternative names: Arsenical pump-driving ATPase, Arsenite-stimulated ATPase, Guided entry of tail-anchored proteins factor 3, ATPase, Transmembrane domain recognition complex 40 kDa ATPase subunit, hARSA-I, hASNA-I

All UniProt accessions (1): O43681

UniProt curated annotations — full annotation on UniProt →

Function. ATPase required for the post-translational delivery of tail-anchored (TA) proteins to the endoplasmic reticulum. Recognizes and selectively binds the transmembrane domain of TA proteins in the cytosol. This complex then targets to the endoplasmic reticulum by membrane-bound receptors GET1/WRB and CAMLG/GET2, where the tail-anchored protein is released for insertion. This process is regulated by ATP binding and hydrolysis. ATP binding drives the homodimer towards the closed dimer state, facilitating recognition of newly synthesized TA membrane proteins. ATP hydrolysis is required for insertion. Subsequently, the homodimer reverts towards the open dimer state, lowering its affinity for the GET1-CAMLG receptor, and returning it to the cytosol to initiate a new round of targeting. May be involved in insulin signaling.

Subunit / interactions. Homodimer. Component of the Golgi to ER traffic (GET) complex, which is composed of GET1/WRB, CAMLG/GET2 and GET3/TRC40. Within the complex, CAMLG and GET1 form a heterotetramer which is stabilized by phosphatidylinositol binding and which binds to the GET3 homodimer. Interacts with CAMLG (via N-terminus). GET3 shows a higher affinity for CAMLG than for GET1. Interacts with SERP1 and SEC61B. Interacts with GET4.

Subcellular location. Cytoplasm. Endoplasmic reticulum. Nucleus. Nucleolus.

Tissue specificity. Expressed in the epithelial cells of the liver, kidney, and stomach wall, in the adrenal medulla, in the islet cells of the pancreas, in the red pulp of the spleen, and in cardiac and skeletal muscle.

Disease relevance. Cardiomyopathy, dilated, 2H (CMD2H) [MIM:620203] A form of dilated cardiomyopathy, a disorder characterized by ventricular dilation and impaired systolic function, resulting in congestive heart failure and arrhythmia. Patients are at risk of premature death. CMD2H is an autosomal recessive form characterized by rapid progression and death in early infancy. The disease is caused by variants affecting the gene represented in this entry.

Similarity. Belongs to the arsA ATPase family.

RefSeq proteins (3): NP_001358417, NP_001358418, NP_004308* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR016300	ATPase_ArsA/GET3	Family
IPR025723	ArsA/GET3_ATPase-like	Domain
IPR027417	P-loop_NTPase	Homologous_superfamily
IPR027542	ATPase_ArsA/GET3_euk	Family

Pfam: PF02374

Enzyme classification (BRENDA)

• EC 7.3.2.7 — arsenite-transporting ATPase (BRENDA: 14 organisms, 34 substrates, 5 inhibitors, 15 Km, 0 kcat entries)

Substrate kinetics (BRENDA)

3 substrates with measured Km, best-characterized 3. Km ranges are aggregated across organisms/conditions.

Substrate	Km (mM)	Measurements
ATP	0.021–2	11
ARSENITE	0.1	1
SB3+	—	1

Catalyzed reactions (Rhea)

• ATP + H2O = ADP + phosphate + H(+) (RHEA:13065)

UniProt features (56 total): helix 17, binding site 12, strand 9, turn 5, sequence variant 4, sequence conflict 3, mutagenesis site 2, initiator methionine 1, chain 1, modified residue 1, active site 1

Structure

Experimental structures (PDB)

4 structures by resolution:

PDB	Title	Method	Resolution (Å)
8CQZ	Homo sapiens Get3 in complex with the Get1 cytoplasmic domain	X-RAY DIFFRACTION	2.8
8CR1	Homo sapiens Get1/Get2 heterotetramer in complex with a Get3 dimer	ELECTRON MICROSCOPY	3.2
6SO5	Homo sapiens WRB/CAML heterotetramer in complex with a TRC40 dimer	ELECTRON MICROSCOPY	4.2
8CR2	Homo sapiens Get1/Get2 heterotetramer (a3’ deletion variant) in complex with a Get3 dimer	ELECTRON MICROSCOPY	4.2

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-O43681-F1	79.69	0.50

Human Protein Atlas

Protein class: Transporters, Primary Active Transporters, Predicted intracellular proteins, Essential proteins

Protein evidence: Evidence at protein level

Subcellular location (HPA, imaging): nucleoli; nucleoplasm

Antibody reliability (HPA): IH approved · IF enhanced

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Catalytic / active sites (1)

Position	Role
74

Ligand- & substrate-binding residues (12)

Position	Role
278	ATP
289	Zn(2+)
292	Zn(2+)
319	ATP
321	ATP
45	ATP
46	ATP
49	ATP
50	ATP
51	ATP
52	ATP
251	ATP

Post-translational modifications (1)

Type	Positions
N-acetylalanine	2

Mutagenesis-validated functional residues (2)

Position	Phenotype
46	abolishes atpase activity, dominantly inhibits the ta protein insertion pathway.
86	reduces ta protein insertion pathway.

Function

Pathways and Gene Ontology

Reactome pathways

0 curated (TAS) of 2; 0 disease pathways. Curated-first; evidence = TAS (manually curated) vs IEA (electronic inference).

2 pathways:

ID	Pathway	Evidence
R-HSA-9609523	Insertion of tail-anchored proteins into the endoplasmic reticulum membrane	electronic
R-HSA-9609507	Protein localization	—

MSigDB gene sets: 179 (showing top): STARK_PREFRONTAL_CORTEX_22Q11_DELETION_DN, IVANOVA_HEMATOPOIESIS_LATE_PROGENITOR, DACOSTA_UV_RESPONSE_VIA_ERCC3_UP, SHIPP_DLBCL_CURED_VS_FATAL_DN, MODULE_70, MARTINEZ_RB1_TARGETS_UP, RICKMAN_METASTASIS_DN, GOBP_ESTABLISHMENT_OF_PROTEIN_LOCALIZATION_TO_MEMBRANE, GOBP_ENDOMEMBRANE_SYSTEM_ORGANIZATION, CYTAGCAAY_UNKNOWN, GOBP_PROTEIN_LOCALIZATION_TO_ORGANELLE, USF_02, GOBP_MEMBRANE_ORGANIZATION, GRUETZMANN_PANCREATIC_CANCER_UP, GOBP_ENDOPLASMIC_RETICULUM_ORGANIZATION

GO Biological Process (2): protein insertion into ER membrane (GO:0045048), tail-anchored membrane protein insertion into ER membrane (GO:0071816)

GO Molecular Function (7): ATP binding (GO:0005524), ATP hydrolysis activity (GO:0016887), metal ion binding (GO:0046872), protein carrier activity (GO:0140597), nucleotide binding (GO:0000166), protein binding (GO:0005515), hydrolase activity (GO:0016787)

GO Cellular Component (7): nucleoplasm (GO:0005654), nucleolus (GO:0005730), cytoplasm (GO:0005737), endoplasmic reticulum membrane (GO:0005789), GET complex (GO:0043529), extracellular exosome (GO:0070062), endoplasmic reticulum (GO:0005783)

Reactome top-level categories

1 top-level categories:

Category	Pathways
Protein localization	1

GO top-level categories

27 GO namespaces:

Category	Terms
nuclear lumen	2
cellular anatomical structure	2
endoplasmic reticulum organization	1
protein localization to organelle	1
protein insertion into membrane	1
protein insertion into ER membrane	1
adenyl ribonucleotide binding	1
purine ribonucleoside triphosphate binding	1
anion binding	1
ribonucleoside triphosphate phosphatase activity	1
ATP-dependent activity	1
cation binding	1
molecular carrier activity	1
nucleoside phosphate binding	1
heterocyclic compound binding	1
binding	1
catalytic activity	1
intracellular membraneless organelle	1
intracellular anatomical structure	1
organelle membrane	1
nuclear outer membrane-endoplasmic reticulum membrane network	1
endoplasmic reticulum subcompartment	1
endoplasmic reticulum protein-containing complex	1
extracellular vesicle	1
cytoplasm	1
endomembrane system	1
intracellular membrane-bounded organelle	1

Experimentally-supported GO annotations

GO terms backed by direct experimental evidence (ECO experimental codes) — 8 of 16 annotations. The rest are phylogenetic / computational / electronic (IEA).

8 experimentally-supported GO terms:

GO term	NS	Evidence
tail-anchored membrane protein insertion into ER membrane	BP	direct assay
GET complex	CC	direct assay
endoplasmic reticulum membrane	CC	direct assay
extracellular exosome	CC	high-throughput assay
nucleolus	CC	direct assay
nucleoplasm	CC	direct assay
ATP hydrolysis activity	MF	direct assay
protein carrier activity	MF	direct assay

Protein interactions and networks

STRING

showing 15 of 1,738 interactions by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
GET3	GET4	Q7L5D6	992
GET3	UBL4A	P11441	982
GET3	GET1	O00258	922
GET3	SGTA	O43765	819
GET3	CAMLG	P49069	812
GET3	BAG6	P46379	750
GET3	SEC61A1	P38378	728
GET3	SRP54	P13624	698
GET3	STX5	Q13190	667
GET3	PEX3	P56589	645
GET3	PEX19	P40855	641
GET3	PEX26	Q7Z412	639
GET3	ARSD	P51689	621
GET3	TMEM208	Q9BTX3	617
GET3	RNF126	Q9BV68	595

IntAct

Human interaction partners of GET3 in IntAct, one row per partner (best MIscore; records = supporting IntAct interaction records).

showing 30 of 44 partners by confidence:

Partner	Interaction type	MIscore	Records
CAMLG	association	0.820	6
GET4	physical association	0.800	7
GPX7	physical association	0.720	6
GET1	association	0.640	4
AGR2	physical association	0.560	7
ASPH	physical association	0.560	6
RCN1	physical association	0.560	5
CPR5	physical association	0.560	3
CREB3L4	physical association	0.560	3
CSPG5	physical association	0.560	3
DDIT4L	physical association	0.560	3
EMSY	physical association	0.560	3
FAM163A	physical association	0.560	3
FAM209A	physical association	0.560	3
FKBP7	physical association	0.560	3
GOLM1	physical association	0.560	3
GPX8	physical association	0.560	3
HILPDA	physical association	0.560	3
IGFBP6	physical association	0.560	3
KCNE4	physical association	0.560	3
KCNE5	physical association	0.560	3
LDLRAD4	physical association	0.560	3
PDIA6	physical association	0.560	3
PEX14	physical association	0.560	3
PGRMC1	physical association	0.560	3
PGRMC2	physical association	0.560	3
PRB3	physical association	0.560	3
PRR4	physical association	0.560	3
RHEX	physical association	0.560	3
SMIM19	physical association	0.560	3

SIGNOR signaling

1 signaling interactions:

A	Effect	B	Mechanism
GET3	“form complex”	“GET complex”	binding

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 44 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs)	5	16.6×	4e-04

Disease & clinical

Genetic variants

Variant evidence for GET3: 42 ClinVar records (1 pathogenic / likely pathogenic). Per-variant detail is on Sugi Variant.

ClinVar

42 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	1
Likely pathogenic	0
Uncertain significance	29
Likely benign	1
Benign	0

Top pathogenic / likely-pathogenic (1)

Showing all 1 pathogenic / likely-pathogenic ClinVar records, ranked by ClinVar review status (expert panel → multiple submitters → single submitter), then by number of submitting labs.

Variant ID	HGVS	Classification	Review	Submitters
2443825	NM_004317.4(GET3):c.488T>C (p.Val163Ala)	Pathogenic	no assertion criteria provided	1

Per-variant reference — Sugi Variant

Explore GET3’s pathogenic and likely-pathogenic variants individually — each with its ClinVar classification and conditions, applied ACMG criteria (ClinGen expert panel, where curated), the calibrated in-silico predictors (AlphaMissense, REVEL, SaProt, conservation), gnomAD frequency, and the predictor-disagreement QC signal — on Sugi Variant.

SpliceAI

Top 10 splice-impact sites by Δscore (adjacent positions with the same effect merged into one range; 34 predictions of 453):

Position(s)	Effect	Δscore	Sites
19:12737667–12737668	donor_loss	1.0000	4
19:12745367–12745368	acceptor_gain	1.0000	2
19:12745375–12745376	acceptor_loss	1.0000	5
19:12745508	donor_gain	1.0000
19:12745526–12745527	donor_loss	1.0000	5
19:12745739	donor_gain	1.0000
19:12747305–12747306	donor_loss	1.0000	4
19:12747393–12747394	acceptor_loss	1.0000	6
19:12747593–12747594	donor_loss	1.0000	5
19:12747938	acceptor_gain	1.0000

AlphaMissense

1,397 missense substitutions predicted likely pathogenic (of 2,327 scored), across 285 residues. Top 20 hotspot residues, ranked by the number of likely-pathogenic substitutions (of those reachable by a single-nucleotide change), then by mean score:

Residue	Likely-pathogenic substitutions	Mean am_pathogenicity	Max am_pathogenicity
M103	9	0.928	0.996
D74	8	1.000	1.000
D166	8	1.000	1.000
D81	8	0.999	1.000
H172	8	0.999	1.000
H77	8	0.997	1.000
D143	8	0.994	0.998
F41	8	0.992	0.999
F165	8	0.992	0.999
F244	8	0.992	1.000
N278	8	0.986	1.000
F83	8	0.985	0.999
F236	8	0.985	0.999
D271	8	0.979	0.993
D312	8	0.979	0.995
N78	8	0.978	1.000
F252	8	0.978	1.000
F87	8	0.973	0.999
F179	8	0.963	0.994
D106	8	0.956	0.993

HPA cancer prognostics

RNA cancer specificity: Low cancer specificity

Human Protein Atlas survival analysis — favorable = higher expression predicts better survival.

1 prognostic cancer types:

Cancer	Prognostic	p-value
Kidney Renal Clear Cell Carcinoma (TCGA)	favorable	2.37e-08

Disease associations

OMIM: gene MIM:601913 | disease phenotypes: MIM:620203

GenCC curated gene-disease

2 curated gene-disease records:

Disease	Classification	Inheritance	Records
cardiomyopathy, dilated, 2H	Limited	Autosomal recessive
acute proliferative glomerulonephritis	Limited	Autosomal recessive

ClinGen Gene-Disease Validity

Expert-panel classifications — Definitive > Strong > Moderate > Limited > Disputed > Refuted.

1 validity classifications:

Disease	Classification	Inheritance
cardiomyopathy, dilated, 2H	Limited	AR

Genomics England panels (PanelApp)

Clinical diagnostic gene panels including this gene (2 panels, 0 green/diagnostic-grade). Confidence: green = diagnostic, amber = moderate.

2 panels:

Panel	Rating
Paediatric or syndromic cardiomyopathy	amber
Unexplained death in infancy and sudden unexplained death in childhood	amber

Mondo (2): cardiomyopathy, dilated, 2H (MONDO:0859358), acute proliferative glomerulonephritis (MONDO:0001644)

HPO phenotypes

22 phenotypes (HPO-id order):

HPO	Term
HP:0000007	Autosomal recessive inheritance
HP:0000407	Sensorineural hearing impairment
HP:0000969	Edema
HP:0001635	Congestive heart failure
HP:0001644	Dilated cardiomyopathy
HP:0001684	Secundum atrial septal defect
HP:0001727	Thromboembolic stroke
HP:0002789	Tachypnea
HP:0002875	Exertional dyspnea
HP:0003198	Myopathy
HP:0003457	EMG abnormality
HP:0003623	Neonatal onset
HP:0003811	Neonatal death
HP:0006543	Cardiorespiratory arrest
HP:0011623	Muscular ventricular septal defect
HP:0011675	Arrhythmia
HP:0011968	Feeding difficulties
HP:0012378	Fatigue
HP:0012664	Reduced left ventricular ejection fraction
HP:0012764	Orthopnea
HP:0025169	Left ventricular systolic dysfunction
HP:0100578	Lipoatrophy

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL6066311 (SINGLE PROTEIN)

PharmGKB: 1 entry (CPIC guideline: no)

Binding affinities (BindingDB)

1 measured of 1 human assays (1 total across all organisms); most potent 1 below. Values come from heterogeneous assays and are not directly comparable.

Ligand	Measure	Value
CHEMBL5653589	KD	1440 nM

ChEMBL bioactivities

2 potent at pChembl≥5 of 2 total, top 2 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
7.78	Kd	16.48	nM	CHEMBL5653589
7.78	ED50	16.48	nM	CHEMBL5653589

PubChem BioAssay actives

1 with measured affinity, of 2 total; 1 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
4-methyl-3-[(2-methyl-6-pyridin-3-ylpyrazolo[3,4-d]pyrimidin-4-yl)amino]-N-[3-(trifluoromethyl)phenyl]benzamide	2147897: Binding affinity to human ASNA1 incubated for 45 mins by Kinobead based pull down assay	kd	0.0165	uM

CTD chemical–gene interactions

27 total (human), top 27 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
sodium arsenite	increases activity, increases expression	2
aristolochic acid I	increases expression	1
triphenyl phosphate	affects expression	1
alpha-pinene	affects cotreatment, increases oxidation, increases abundance	1
pirinixic acid	affects binding, decreases expression, increases activity	1
bisphenol A	increases expression	1
perfluorooctanoic acid	increases expression	1
methacrylaldehyde	affects cotreatment, increases oxidation, increases abundance	1
perfluorooctane sulfonic acid	increases expression	1
CGP 52608	affects binding, increases reaction	1
nutlin 3	affects cotreatment, increases secretion	1
Arsenic Trioxide	increases expression	1
Acrolein	affects cotreatment, increases oxidation, increases abundance	1
Air Pollutants	affects cotreatment, increases abundance, increases oxidation	1
Arbutin	decreases expression	1
Benzo(a)pyrene	affects methylation	1
Cisplatin	affects response to substance	1
Dactinomycin	affects cotreatment, increases secretion	1
Doxorubicin	decreases expression	1
Ivermectin	decreases expression	1
Lead	decreases expression	1
Ozone	affects cotreatment, increases oxidation, increases abundance	1
Smoke	decreases expression	1
Tretinoin	increases expression	1
Valproic Acid	increases expression	1
Aflatoxin B1	increases expression	1
Volatile Organic Compounds	affects cotreatment, increases oxidation	1

ChEMBL screening assays

1 unique, capped per target: 1 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL5650939	Binding	Binding affinity to human ASNA1 incubated for 45 mins by Kinobead based pull down assay	NVP-BHG712: Effects of Regioisomers on the Affinity and Selectivity toward the EPHrin Family. — *ChemMedChem*

Clinical trials (associated diseases)

Via MONDO — disease-level, not drug-specific.

showing 60 of 300 trials:

NCT	Phase	Status	Title
NCT00029224	Phase 4	COMPLETED	Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions
NCT00035997	Phase 4	COMPLETED	Open-label Trial on the Effect of I.V. Zoledronic Acid 4 mg on Bone Density in Hormone Sensitive Prostate Cancer Patients With Bone Metastasis
NCT00063609	Phase 4	COMPLETED	The Effect of Zoledronic Acid on Bone Loss in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy
NCT00103623	Phase 4	SUSPENDED	The Plenaxis® Experience Study
NCT00106392	Phase 4	COMPLETED	A Safety and Efficacy Study of Prograf in the Prevention of Erectile Dysfunction After Radical Prostatectomy
NCT00185029	Phase 4	UNKNOWN	MR-Lymphography and Lymph Node Staging in Prostate Cancer
NCT00199485	Phase 4	COMPLETED	Angelica Sinensis for the Treatment of Hot Flashes in Men Undergoing LHRH Therapy for Prostate Cancer
NCT00219219	Phase 4	COMPLETED	Zoledronic Acid in the Prevention of Skeletal-related Events in Hormone Refractory and Hormone-sensitive Prostate Cancer Patients With Bone Metastases
NCT00219271	Phase 4	COMPLETED	Effect Of Zoledronic Acid On Circulating And Bone Marrow-Residing Prostate Cancer Cells In Patients With Clinically Localized Prostate Cancer
NCT00237146	Phase 4	COMPLETED	Study to Evaluate Zoledronic Acid on Quality of Life and Skeletal-related Events as Adjuvant Treatment in Patients With Hormone-naïve Prostate Cancer and Bone Metastasis Who Have Undergone Orchiectomy
NCT00242554	Phase 4	COMPLETED	Open-label Phase IV Clinical Trial to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastases
NCT00280098	Phase 4	COMPLETED	Docetaxel in the Treatment of Hormone Refractory Prostate Cancer
NCT00293696	Phase 4	COMPLETED	Casodex/Zoladex Biomarkers in Localised Prostate Cancer
NCT00334139	Phase 4	COMPLETED	Effect of Zoledronic Acid on Bone Metabolism in Patients With Bone Metastasis and Prostate or Breast Cancer
NCT00375765	Phase 4	COMPLETED	Effects On Dihydrotestosterone Regulated Gene Expression In Benign Prostatic Hyperplasia Or Prostate Cancer
NCT00391690	Phase 4	COMPLETED	Evaluation of Bone Markers as Diagnostic Tools for Early Detection of Bone Metastases in Patients With High Risk Prostate Cancer
NCT00422708	Phase 4	COMPLETED	Local Anesthesia for Prostate Biopsy
NCT00526331	Phase 4	COMPLETED	Evaluation of Arterial Pressure Based Cardiac Output for Goal-Directed Perioperative Therapy
NCT00590213	Phase 4	COMPLETED	Compare the Value of Prophylactic Versus Therapeutic Breast Radiotherapy in CASODEX
NCT00629330	Phase 4	TERMINATED	Dissemination of Prostate Cancer Screening to PCP’s in African American Communities
NCT00771966	Phase 4	COMPLETED	Radical Prostatectomy and Perioperative Fluid Therapy
NCT00805701	Phase 4	COMPLETED	Study Assessing The Efficacy And Safety Of Avodart (Dutasteride) At Improving Urinary Symptoms In Men With Prostate Cancer Who Are Undergoing Seed Implantation
NCT00859027	Phase 4	COMPLETED	Effect Of Risedronate On Bone Mass In Older Men Receiving Neoadjuvant Therapy For Prostate Cancer
NCT00906269	Phase 4	UNKNOWN	Can Hyperbaric Oxygen Improve Erectile Function Following Surgery for Prostate Cancer
NCT00953277	Phase 4	COMPLETED	Study of Nerve Reconstruction Using AVANCE in Subjects Who Undergo Robotic Assisted Prostatectomy for Treatment of Prostate Cancer
NCT00982800	Phase 4	COMPLETED	Does Postoperative Gabapentin Reduce Pain, Opioid Consumption and Anxiety and Have a Positive Effect on Health Related Quality of Life After Radical Prostatectomy?
NCT01083199	Phase 4	COMPLETED	Global Performance Evaluation of the AMS CONTINUUM™ Device
NCT01136226	Phase 4	COMPLETED	Evaluate Recovery of Testosterone for Patients Using Eligard
NCT01161563	Phase 4	COMPLETED	Randomized Crossover Trial to Assess the Tolerability of Gonadotropin Releasing Hormone (GnRH) Analogue Administration
NCT01230905	Phase 4	COMPLETED	Study to Monitor the Effects of Androgen Suppression Treatment on the Heart
NCT01296672	Phase 4	COMPLETED	3 Month Finasteride Challenge Test Can Significantly Improve the Performance of Screening for Prostate Cancer
NCT01365143	Phase 4	TERMINATED	Prospective Randomized Trial Comparing Robotic Versus Open Radical Prostatectomy
NCT01379742	Phase 4	UNKNOWN	Comparison of Between ThinSeed™ and OncoSeed™ for Permanent Prostate Brachytherapy
NCT01486563	Phase 4	COMPLETED	Hydroxyethyl Starch and Renal Function After Radical Prostatectomy
NCT01511874	Phase 4	COMPLETED	Efficacy and Safety Study of ELIGARD 22.5mg With Prostate Cancer
NCT01512472	Phase 4	TERMINATED	Firmagon (Degarelix) Intermittent Therapy
NCT01547416	Phase 4	COMPLETED	The Effect of Combined General/Epidural Anesthesia Versus General Anesthesia on Diaphragmatic Function
NCT01571544	Phase 4	COMPLETED	The Use of Thermal Suits as Preventing Hypothermia During Surgery
NCT01581749	Phase 4	UNKNOWN	Evaluation of Truebeam for Low-Intermediate Risk Prostate Cancer
NCT01649635	Phase 4	COMPLETED	Study of Cabazitaxel Combined With Prednisone and Prophylaxis of Neutropenia Complications in the Treatment of Patients With Metastatic Castration-resistant Prostate Cancer
NCT01673984	Phase 4	TERMINATED	GP Extended Action Triptorelin
NCT01753297	Phase 4	COMPLETED	A Study of Immediate 9 Months Adjuvant Hormone Therapy With Triptorelin 11.25 mg Versus Active Surveillance After Radical Prostatectomy in High Risk Prostate Cancer Patients.
NCT01794793	Phase 4	COMPLETED	Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies
NCT01950871	Phase 4	TERMINATED	Prostate Guided Biopsy Study Evaluating the Diagnostic Performance of Prostate HistoScanning
NCT01995513	Phase 4	COMPLETED	Safety Study of Continued Enzalutamide Treatment In Prostate Cancer Patients
NCT02102646	Phase 4	COMPLETED	MRI Substudy; Metabolic Changes Due to Iatrogenic Hypogonadism
NCT02116582	Phase 4	COMPLETED	A Study to Evaluate Enzalutamide After Abiraterone in Metastatic Castration-Resistant Prostate Cancer
NCT02149628	Phase 4	COMPLETED	The Effect of Propofol Based Total Intravenous Anesthesia on Oxidative Stress and Nitric Oxide
NCT02405858	Phase 4	COMPLETED	A Study of Abiraterone Acetate in Metastatic Castration-Resistant Prostate Cancer Participants Who Responded Poorly to the First-line Combined Androgen Blockade Therapy
NCT02441517	Phase 4	TERMINATED	A Study of Enzalutamide Re-treatment in Metastatic Castration-resistant Prostate Cancer After Docetaxel and/or Cabazitaxel Treatment
NCT02441894	Phase 4	COMPLETED	Combination of Cabazitaxel With Prednisolone With Primary Prophylaxis With PEG-G-CSF in Treatment of Patients With Prostate Cancer
NCT02475057	Phase 4	COMPLETED	Endothelial Function in Prostate Cancer Patients on Degarelix vs. Luteinizing Hormone-Releasing Hormone Agonists
NCT02511665	Phase 4	UNKNOWN	Metformin And Longevity
NCT02651948	Phase 4	COMPLETED	Transperineal, MRI-guided, Prostate Biopsy
NCT02721433	Phase 4	COMPLETED	4-weekly Versus 12-weekly Administration of Bone-targeted Agents in Patients With Bone Metastases
NCT02726009	Phase 4	COMPLETED	A Trial to Evaluate Safety of Firmagon® (Degarelix) in Indian Patients Diagnosed With Advanced Hormone-dependent Prostate Cancer
NCT02749825	Phase 4	TERMINATED	Comparison of Trelstar Versus Lupron or Zoladex in Advanced Prostate Cancer
NCT02757365	Phase 4	UNKNOWN	Efficiency Study of Aspirin to Prevent the Occurrence of Prostate Cancer
NCT02773251	Phase 4	COMPLETED	The Effect of Guardix-solution for the Prevention of Postoperative Intestinal Adhesion and Intestinal Obstruction After Laparoscopic Pelvic Cavity Surgery
NCT02812186	Phase 4	COMPLETED	Deep Versus Moderate Neuromuscular Blockade During Laparoscopic Surgery

Predicted chemistry — Sugi Predict

The predicted patent-compound landscape for GET3 across ~30M SureChEMBL compounds — explore on Sugi Predict.